Targeting angiogenesis in metastatic breast cancer

Sangeetha Reddy, Michael Raffin, Virginia Kaklamani

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Angiogenesis has become an important target in the treatment of several solid tumors, including breast cancer. As monotherapy, antiangiogenic agents have demonstrated limited activity in metastatic breast cancer (MBC); therefore, they have generally been developed for use in combination with chemotherapies. Thus far, the experience with antiangiogenic agents for MBC has been mixed. The results from one study assessing addition of the monoclonal antibody bevacizumab to paclitaxel led to approval of bevacizumab for MBC. However, the modest improvement of progression-free survival rates in subsequent MBC studies has led to reappraisal of bevacizumab. Phase III studies have not produced evidence supporting use of the multikinase inhibitor sunitinib alone or in combination with MBC chemotherapy. Experience with sorafenib in a phase IIb program indicates potential when used in select combinations, particularly with capecitabine; however, phase III confirmatory data are needed. Although antiangiogenic therapies combined with chemotherapy have increased progressionfree survival rates for patients with MBC, increases in overall survival times have not been observed. Some studies have tried to combine antiangiogenic agents such as bevacizumab and sunitinib or sorafenib, but that approach has been limited because of toxicity concerns. Sequential use of antiangiogenic agents with differing mechanisms of action may be an effective approach. Despite setbacks, angiogenesis will likely remain an important target of treatment for selected patients with MBC.

Original languageEnglish (US)
Pages (from-to)1014-1026
Number of pages13
JournalOncologist
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Breast Neoplasms
Angiogenesis Inhibitors
Survival Rate
Drug Therapy
Paclitaxel
Combination Drug Therapy
Disease-Free Survival
Therapeutics
Monoclonal Antibodies
Survival
Bevacizumab
Neoplasms
sorafenib
sunitinib

Keywords

  • Angiogenesis
  • Bevacizumab
  • Everolimus
  • Metastatic breast cancer
  • Sorafenib
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting angiogenesis in metastatic breast cancer. / Reddy, Sangeetha; Raffin, Michael; Kaklamani, Virginia.

In: Oncologist, Vol. 17, No. 8, 01.08.2012, p. 1014-1026.

Research output: Contribution to journalArticle

Reddy, Sangeetha ; Raffin, Michael ; Kaklamani, Virginia. / Targeting angiogenesis in metastatic breast cancer. In: Oncologist. 2012 ; Vol. 17, No. 8. pp. 1014-1026.
@article{0c40b0ec4ba9402eaa93455b4b57d137,
title = "Targeting angiogenesis in metastatic breast cancer",
abstract = "Angiogenesis has become an important target in the treatment of several solid tumors, including breast cancer. As monotherapy, antiangiogenic agents have demonstrated limited activity in metastatic breast cancer (MBC); therefore, they have generally been developed for use in combination with chemotherapies. Thus far, the experience with antiangiogenic agents for MBC has been mixed. The results from one study assessing addition of the monoclonal antibody bevacizumab to paclitaxel led to approval of bevacizumab for MBC. However, the modest improvement of progression-free survival rates in subsequent MBC studies has led to reappraisal of bevacizumab. Phase III studies have not produced evidence supporting use of the multikinase inhibitor sunitinib alone or in combination with MBC chemotherapy. Experience with sorafenib in a phase IIb program indicates potential when used in select combinations, particularly with capecitabine; however, phase III confirmatory data are needed. Although antiangiogenic therapies combined with chemotherapy have increased progressionfree survival rates for patients with MBC, increases in overall survival times have not been observed. Some studies have tried to combine antiangiogenic agents such as bevacizumab and sunitinib or sorafenib, but that approach has been limited because of toxicity concerns. Sequential use of antiangiogenic agents with differing mechanisms of action may be an effective approach. Despite setbacks, angiogenesis will likely remain an important target of treatment for selected patients with MBC.",
keywords = "Angiogenesis, Bevacizumab, Everolimus, Metastatic breast cancer, Sorafenib, Sunitinib",
author = "Sangeetha Reddy and Michael Raffin and Virginia Kaklamani",
year = "2012",
month = "8",
day = "1",
doi = "10.1634/theoncologist.2012-0043",
language = "English (US)",
volume = "17",
pages = "1014--1026",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "8",

}

TY - JOUR

T1 - Targeting angiogenesis in metastatic breast cancer

AU - Reddy, Sangeetha

AU - Raffin, Michael

AU - Kaklamani, Virginia

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Angiogenesis has become an important target in the treatment of several solid tumors, including breast cancer. As monotherapy, antiangiogenic agents have demonstrated limited activity in metastatic breast cancer (MBC); therefore, they have generally been developed for use in combination with chemotherapies. Thus far, the experience with antiangiogenic agents for MBC has been mixed. The results from one study assessing addition of the monoclonal antibody bevacizumab to paclitaxel led to approval of bevacizumab for MBC. However, the modest improvement of progression-free survival rates in subsequent MBC studies has led to reappraisal of bevacizumab. Phase III studies have not produced evidence supporting use of the multikinase inhibitor sunitinib alone or in combination with MBC chemotherapy. Experience with sorafenib in a phase IIb program indicates potential when used in select combinations, particularly with capecitabine; however, phase III confirmatory data are needed. Although antiangiogenic therapies combined with chemotherapy have increased progressionfree survival rates for patients with MBC, increases in overall survival times have not been observed. Some studies have tried to combine antiangiogenic agents such as bevacizumab and sunitinib or sorafenib, but that approach has been limited because of toxicity concerns. Sequential use of antiangiogenic agents with differing mechanisms of action may be an effective approach. Despite setbacks, angiogenesis will likely remain an important target of treatment for selected patients with MBC.

AB - Angiogenesis has become an important target in the treatment of several solid tumors, including breast cancer. As monotherapy, antiangiogenic agents have demonstrated limited activity in metastatic breast cancer (MBC); therefore, they have generally been developed for use in combination with chemotherapies. Thus far, the experience with antiangiogenic agents for MBC has been mixed. The results from one study assessing addition of the monoclonal antibody bevacizumab to paclitaxel led to approval of bevacizumab for MBC. However, the modest improvement of progression-free survival rates in subsequent MBC studies has led to reappraisal of bevacizumab. Phase III studies have not produced evidence supporting use of the multikinase inhibitor sunitinib alone or in combination with MBC chemotherapy. Experience with sorafenib in a phase IIb program indicates potential when used in select combinations, particularly with capecitabine; however, phase III confirmatory data are needed. Although antiangiogenic therapies combined with chemotherapy have increased progressionfree survival rates for patients with MBC, increases in overall survival times have not been observed. Some studies have tried to combine antiangiogenic agents such as bevacizumab and sunitinib or sorafenib, but that approach has been limited because of toxicity concerns. Sequential use of antiangiogenic agents with differing mechanisms of action may be an effective approach. Despite setbacks, angiogenesis will likely remain an important target of treatment for selected patients with MBC.

KW - Angiogenesis

KW - Bevacizumab

KW - Everolimus

KW - Metastatic breast cancer

KW - Sorafenib

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84865227347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865227347&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2012-0043

DO - 10.1634/theoncologist.2012-0043

M3 - Article

C2 - 22843553

AN - SCOPUS:84865227347

VL - 17

SP - 1014

EP - 1026

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 8

ER -